At a glance
- Buserelin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 1,496 publications mentioning it, including 166 randomized controlled trials and 486 animal-only studies.
- ClinicalTrials.gov lists 42 registered studies testing it (4 active).
- FDA's adverse event system (FAERS) holds 232 reports mentioning it; 226 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Ovulation Timing After Recombinant Human Chorionic Gonadotropin, Gonadorelin, or Buserelin Under Estrus-Triggered and Fixed-Time Treatment Protocols for Artificial Insemination in Sows.
- Ex Vivo Evaluation of Buserelin Permeation Across Porcine Endometrial Tissue: A Pilot Study.
- Field Implementation of Buserelin-Supplemented Boar Semen Protocol at the First Insemination: Farrowing Rate and Litter Size in Gilts and Sows Under Tropical Conditions.
- Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?
- Buserelin Improves Ovulation-Embryo Synchrony Compared With hCG After eCG-Induced Superovulation in Donor Sows.
- Superovulation with eCG alone or combined with the GnRH analogue buserelin improves transferable embryo production in weaned sows without affecting day 6 embryo morphological, cellular, and transcriptomic parameters.
- Optimizing ovulation synchronization in Holstein heifers: implementing a half-dose GnRH analogue (Buserelin Acetate) in a nanofabricated form within the ovsynch protocol to enhance the ovarian activity and reproductive performance outcomes.
- Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis.
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
- Effect of buserelin acetate at artificial insemination on pregnancy per AI in dairy cows inseminated with sexed semen.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 42
- Active
- 4
- With posted results
- 8
Conditions studied
Show 32 more studies
All 42 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 232
- Serious
- 226
- With death outcome
- 21
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.